Lupin Limited, a prominent Indian pharmaceutical powerhouse, recently announced a significant stride in the domain of eye care treatments by partnering with Amman Pharmaceuticals Industries (Amman Pharma) to exclusively market and commercialize a Ranibizumab biosimilar. This biosimilar, akin to the widely known Lucentis, is designed to address age-related eye conditions prevalent in the Middle East and select territories, covering Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other GCC countries. This collaboration marks a pivotal step in enhancing the accessibility of advanced healthcare solutions in the MENA region.
Ranibizumab, the focal drug in this partnership, holds critical importance in managing neovascular age-related macular degeneration (AMD) and macular oedema. Administered via direct injection into the eye, it operates by impeding the growth of abnormal blood vessels, thereby reducing leakage and forestalling further damage to the retina.
Nilesh Gupta, the Managing Director of Lupin, expressed the company's vision of spearheading a transformation in patients' lives and contributing to a healthier, brighter future for the MENA community. Furthermore, Dr. Cyrus Karkaria, President of Biotechnology at Lupin, underscored the commitment to ensuring widespread access to cutting-edge biologic medications at affordable prices.
Dr. Fadi Alatrash, General Manager of Amman Pharma, emphasized the collaborative commitment to delivering high-quality products and extending access to advanced biosimilars to patients in the region. This partnership is not only set to expand Lupin's biosimilar portfolio but also to solidify its position within the specialized Ophthalmology market.
Lupin's recent financial report for the July-September quarter showcased a remarkable performance, with a staggering 3.77-fold increase in consolidated net profit, amounting to Rs 489.6 crore. The North American sales for the same period surged to Rs 1,866.6 crore, marking a 40.4 per cent increase from the previous year's corresponding quarter and contributing significantly, accounting for 38 per cent of Lupin's global sales.
The strategic alliance between Lupin and Amman Pharma extends beyond mere business interests; it signifies a collective endeavour to advance healthcare access and innovation. By combining Lupin's expertise and Amman Pharma's regional presence, the collaboration promises to make a substantive impact in the MENA healthcare landscape. This joint effort not only represents a significant market strategy but also a commitment to elevating the standard of care and treatment options for those battling age-related eye conditions in the Middle East and select territories.
